Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 7, 2025
Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE)
Cash runway to fund operations out to third quarter of 2026
Read more at globenewswire.comNASDAQ:EPRX (8/1/2025, 8:00:02 PM)
5.26
-0.14 (-2.59%)
Find more stocks in the Stock Screener
